Fibrolamellar Carcinoma (FLC): Treatment in Shanghai for International Patients
Fibrolamellar carcinoma (FLC) is one of the rarest and most distinctive forms of liver cancer. Unlike hepatocellular carcinoma (HCC) — which typically develops in patients with cirrhosis, hepatitis B, or hepatitis C — FLC arises in otherwise healthy livers, most commonly in adolescents and young adults between the ages of 15 and 35. It has no association with alcohol use, viral hepatitis, or metabolic liver disease.
Because FLC is so rare (accounting for fewer than 1% of all primary liver cancers), most oncologists and hepatobiliary surgeons encounter only a handful of cases in their careers. This makes subspecialty expertise and access to high-volume hepatobiliary centers critically important. Shanghai's leading liver surgery programs — among the busiest in the world — offer international patients a meaningful advantage in terms of surgical volume, multidisciplinary expertise, and access to clinical research.
What Makes FLC Different from Other Liver Cancers
Understanding FLC's unique biology is essential for patients navigating treatment decisions:
Molecular Driver — DNAJB1-PRKACA Fusion: In 2014, researchers identified a specific chromosomal deletion (del19q13.11) present in nearly all FLC tumors, resulting in a fusion between the DNAJB1 and PRKACA genes. This fusion activates protein kinase A (PKA) signaling and is now considered the defining molecular hallmark of FLC. It is not inherited and does not appear in normal liver tissue. This discovery has opened the door to targeted therapy research specifically aimed at this fusion.
No Underlying Liver Disease: Because FLC patients typically have normal liver function, they are often better surgical candidates than HCC patients with cirrhosis. This means more aggressive resection is frequently possible, and liver transplantation — when indicated — can be considered without the complications of end-stage liver disease.
Slower Growth, But Late Presentation: FLC tends to grow more slowly than conventional HCC, and patients often present with large tumors or regional lymph node involvement at diagnosis. Despite this, long-term survival after complete surgical resection is significantly better than for HCC, with 5-year survival rates of 40–70% in resected patients reported in specialized series.
AFP Usually Normal: Alpha-fetoprotein (AFP), the standard HCC tumor marker, is typically normal or only mildly elevated in FLC. This means AFP cannot be used to monitor disease response. Alternative markers such as des-gamma-carboxyprothrombin (DCP) and vitamin B12-binding protein may be elevated and are used for surveillance.
Symptoms and Diagnosis
FLC often presents insidiously. Common symptoms include:
- Abdominal pain or discomfort in the right upper quadrant
- A palpable abdominal mass
- Unintentional weight loss
- Fatigue and early satiety
- Rarely, jaundice (if the tumor compresses bile ducts)
Diagnosis is established through a combination of cross-sectional imaging (CT and MRI with liver protocol), and confirmed by biopsy with histopathological review. The characteristic appearance on pathology — large polygonal tumor cells with abundant eosinophilic cytoplasm separated by dense fibrous lamellae — gives the disease its name. Molecular confirmation of the DNAJB1-PRKACA fusion is increasingly recommended, particularly for atypical cases.
Treatment: Surgery Is the Cornerstone
Complete surgical resection (R0 resection) is the only potentially curative treatment for FLC. The goals of surgery are:
- Removal of the primary tumor with clear margins
- Regional lymph node dissection (FLC has a higher rate of lymph node involvement than HCC)
- Preservation of adequate future liver remnant (FLR) — typically at least 20–25% of total liver volume in a healthy liver
For patients with large tumors or bilateral involvement, techniques such as portal vein embolization (PVE) to induce hypertrophy of the future liver remnant, two-stage hepatectomy, or ALPPS (Associating Liver Partition and Portal vein ligation for Staged hepatectomy) may be employed at high-volume centers. Shanghai's hepatobiliary surgery programs have extensive experience with all of these advanced techniques.
Liver Transplantation: For patients with unresectable FLC confined to the liver, liver transplantation is an option at select centers. Outcomes data for FLC transplantation are limited due to the rarity of the disease, but carefully selected patients — particularly those without extrahepatic disease — can achieve long-term survival. Shanghai's transplant programs are among the most active in Asia.
Systemic Therapy for Advanced or Recurrent FLC
FLC does not respond well to standard HCC systemic therapies such as sorafenib or lenvatinib, which are approved for HCC but have shown limited activity in FLC. This reflects the distinct biology of FLC compared to conventional HCC.
Current systemic approaches for unresectable or metastatic FLC include:
Platinum-based chemotherapy: Regimens such as gemcitabine + oxaliplatin (GEMOX) or cisplatin-based combinations have shown modest activity and remain a standard option for systemic disease.
mTOR inhibitors: Given the role of PKA signaling in FLC biology, mTOR pathway inhibitors (everolimus, temsirolimus) have been explored, with limited but occasionally meaningful responses.
PRKACA-targeted approaches: The DNAJB1-PRKACA fusion is an active area of drug development. Several early-phase clinical trials are evaluating kinase inhibitors and other agents targeting this fusion. Patients with advanced FLC should be evaluated for clinical trial eligibility at every decision point.
Immunotherapy: PD-1/PD-L1 checkpoint inhibitors have been used in FLC with variable results. Tumor mutational burden (TMB) and other biomarkers may help identify patients more likely to respond.
Leading Shanghai Specialists for FLC
Given FLC's rarity, the most important criterion for specialist selection is hepatobiliary surgical volume and experience with complex liver resections, combined with access to a multidisciplinary team that includes hepatology, medical oncology, interventional radiology, and transplant surgery.
Shanghai's leading hepatobiliary centers include:
Zhongshan Hospital (中山医院) — Fudan University: Home to one of China's most celebrated hepatobiliary surgery programs, with particular strength in liver resection for primary liver tumors. The department performs thousands of hepatectomies annually and has extensive experience with complex resections, vascular reconstruction, and ALPPS. CMCS works with leading hepatobiliary surgeons at Zhongshan, including Prof. Fan Jia (樊嘉) and Prof. Zhou Jian (周促), both internationally recognized for their contributions to liver cancer surgery and research.
Eastern Hepatobiliary Surgery Hospital (东方肝胆外科医院) — Naval Medical University: A dedicated hepatobiliary specialty hospital and one of the largest liver surgery centers in the world by volume. Its focus exclusively on liver, biliary, and pancreatic diseases means that even rare entities like FLC are encountered with greater frequency than at general hospitals.
Renji Hospital (仁济医院) — Shanghai Jiao Tong University: Strong hepatobiliary surgery and liver transplantation program, with active clinical research in primary liver tumors.
Multidisciplinary Care: What FLC Patients Need
Because FLC is rare and its optimal management is not fully standardized, multidisciplinary tumor board review is essential. An ideal FLC multidisciplinary team includes:
- Hepatobiliary surgeon with high-volume liver resection experience
- Transplant hepatologist and transplant surgeon (for transplant evaluation)
- Medical oncologist familiar with rare liver tumors and clinical trial access
- Interventional radiologist (for PVE, TACE, or ablation as bridging or palliative options)
- Radiation oncologist (stereotactic body radiotherapy / SBRT may have a role in selected cases)
- Pathologist with expertise in hepatobiliary tumors and molecular diagnostics
CMCS coordinates access to all of these specialties, ensuring that FLC patients receive a comprehensive multidisciplinary evaluation rather than a single-specialty opinion.
What to Prepare Before Your Shanghai Consultation
To enable the most productive initial consultation, FLC patients should gather:
- CT and/or MRI of the abdomen with liver protocol — most recent imaging, digital DICOM files preferred
- PET-CT (if available) for staging assessment
- Pathology report with histological description and, if available, DNAJB1-PRKACA fusion confirmation
- Liver function tests (LFTs, bilirubin, albumin, INR, Child-Pugh score if calculated)
- Tumor markers: AFP, DCP (PIVKA-II), vitamin B12 levels
- Prior treatment records (surgery, chemotherapy, interventional procedures)
- Volumetric liver assessment if prior resection has been performed or is being planned
CMCS provides medical record translation for documents in English, Arabic, French, Russian, and other languages. A remote pre-consultation review by the treating hepatobiliary team is available before any travel to Shanghai is required.
How CMCS Coordinates FLC Care in Shanghai
China Medical Concierge Shanghai (CMCS) is a health management company — not a hospital — that specializes in connecting international patients with Shanghai's leading specialists. For FLC patients, our coordination includes:
- Case triage to the most appropriate hepatobiliary surgeon and oncology team based on disease stage and prior treatment history
- Medical record translation and clinical summary preparation
- Multidisciplinary tumor board submission and review coordination
- Appointment scheduling across surgery, oncology, transplant, and interventional radiology
- On-site interpretation during all consultations and procedures
- Clinical trial eligibility assessment
- Post-treatment follow-up and surveillance coordination
- Liaison with the patient's home oncologist for continuity of care
Contact CMCS to Begin Your FLC Consultation
If you or a family member has been diagnosed with fibrolamellar carcinoma and are considering evaluation or treatment in Shanghai, we encourage you to reach out early. Given the complexity and rarity of FLC, early multidisciplinary review is essential to ensure all treatment options — including surgery, transplantation, and clinical trials — are properly evaluated.
📧 contract@medicalsh.com
💬 WhatsApp: https://wa.me/message/3AM6KAGCW2BAD1
🌐 www.medicalsh.com
CMCS – China Medical Concierge Shanghai connects international patients with Shanghai's leading specialists. We are a health management company, not a hospital. All clinical decisions are made by the treating physician. This guide is for informational purposes only and does not constitute medical advice.
0件のコメント